ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 78 filers reported holding ALX ONCOLOGY HLDGS INC in Q3 2023. The put-call ratio across all filers is 0.07 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $453,120 | -38.8% | 94,400 | -4.3% | 0.00% | -50.0% |
| Q2 2023 | $740,486 | +80.8% | 98,600 | +8.8% | 0.00% | +100.0% |
| Q1 2023 | $409,620 | -59.5% | 90,624 | +0.9% | 0.00% | -66.7% |
| Q4 2022 | $1,011,933 | +9.5% | 89,790 | -7.0% | 0.00% | 0.0% |
| Q3 2022 | $924,000 | +2.2% | 96,524 | -13.6% | 0.00% | +50.0% |
| Q2 2022 | $904,000 | +4.5% | 111,695 | +118.2% | 0.00% | 0.0% |
| Q1 2022 | $865,000 | +71.3% | 51,200 | +117.9% | 0.00% | +100.0% |
| Q4 2021 | $505,000 | -75.2% | 23,500 | -14.9% | 0.00% | -75.0% |
| Q3 2021 | $2,039,000 | +58.7% | 27,600 | +17.4% | 0.00% | +33.3% |
| Q2 2021 | $1,285,000 | -25.9% | 23,500 | 0.0% | 0.00% | -25.0% |
| Q1 2021 | $1,733,000 | +50.0% | 23,500 | +75.4% | 0.00% | +33.3% |
| Q4 2020 | $1,155,000 | – | 13,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |